TÜV Rheinland PTL, LLC
  1. Companies
  2. TÜV Rheinland PTL, LLC
  3. Services
  4. In-Vitro Diagnostic Device Directive ...

In-Vitro Diagnostic Device Directive (IVD)

SHARE

You must comply with the In Vitro Diagnostic Directive (IVDD) 98/79/EC, if you want to market your In Vitro Diagnostic Devices in the EU. As a notified body, accredited to the full scope of IVDD, we can test and certify your medical devices and quality systems. TÜV Rheinland offers a broad range of service for determining compliance with the In-Vitro Diagnostic Device Directive. To achieve certification, our team first determines the correct classification and intended use of the device, followed by an inspection and evaluation of the design of the product, technical documentation, and conformity to the directive. IVD testing is completed by an on-site audit of production facilities and management documentation. TÜV Rheinland can issue IVDD certification following the successful completion of these steps.

Most popular related searches

Product tests and certifications by TÜV Rheinland enables you to:

  • Ensure compliance with legal and regulatory requirements
  • Competitively position your products with our independent third party certification
  • Reach markets faster with our comprehensive range of testing and assessment services
  • Boost confidence in the quality of your IVD devices
  • Benefit from years of experience, expertise and global network

As a notified body, TÜV Rheinland can assist companies acquire worldwide approval of medical devices. We offer a comprehensive range of services for assessing the conformity of In-Vitro Diagnostic Devices.

Steps to acquiring certification include:

1. Definition of the Medical Device and Intended Use
As the manufacturer, you define the intended purpose and classification of your in-vitro diagnostic device.

2. Product Design Examination
For products in Annex II, list A: 
Our experts determine whether all of the product design documentation (design dossier) complies with Directive 98/79/EC. At the same time, we define criteria for batch release. If you pass the design examination, our certification body issues an EC design examination certificate.

32. Technical Documentation Review
A technical documentation review is conducted for checking compliance with the directive.

3. Optional Preliminary Audit
We define the scope of this audit based on your needs. Based on the findings of the audit, a detailed report will be issued highlighting areas with weakness.

4. Initial Certification Audit
Phase 1 
We audit your site to determine whether you are eligible for certification or analyze all the required information about the company. This includes a review of your quality management documentation. An audit report will be issued at the end of the phase 1 audit.

Phase 2 
Based on the audit plan provided prior to the visit, our experts will determine whether your company processes comply with the relevant directives and standards. The audit team includes an expert in the appropriate product category or categories. A detailed audit report with findings will be issued at the end of the visit.

5. Certificate/Approval
If the results of the audit are positive, you receive an approval for the conformity assessment procedure. This is followed by a regular surveillance audit every 12 months and a recertification every 5 years.

6. Declaration of Conformity
Once you have successfully completed the audit, you can issue the declaration of conformity for your products and market them with the CE mark, including the ID of the notified body (0197).

Which products require a conformity assessment by a notified body?

A conformity assessment by a notified body is mandatory for all products specified in Annex II, Lists A and B of Directive 98/79/EC, as well as products designated for self-testing.

List A in Annex II: High-Risk In-Vitro Diagnostic Devices
  • Reagents and reagent products, including related calibrators and control materials for determining the following blood groups: ABO system, rhesus (C, c, D, E, e), and anti-Kell.
  • Reagents and reagent products, including related calibrators and control materials, for detection, confirmation and quantification in human specimens of markers of HIV infection (HIV 1 and 2), HTLV I and II, and hepatitis B, C, and D.
List B in Annex II: Reagents and Reagent Products, including Related Calibrators and Control Materials
  • For determining the blood groups anti-Duffy and anti-Kidd
  • For determining irregular anti-erythrocytic antibodies
  • For detection and quantification in human samples of the following congenital infections: rubella, toxoplasmosis
  • For diagnosing the hereditary disease phenylketonuria
  • For determining the human infections cytomegalovirus and Chlamydia
  • For determining the HLA tissue groups DR, A and B
  • For determining the tumoral marker PSA
  • Designed specifically for evaluating the risk of trisomy 21 (including software)
  • Designed as self-testing devices for measuring blood sugar
IVDs for Self-Testing

Products for self-testing by non-professionals at home (e.g. pregnancy tests or cholesterol tests).